Stefano Frega

Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial

Carmine Pinto, Paolo Andrea Zucali, Maria Pagano et al. · The Lancet Oncology · 2021 · 103 citations

Medicine, Oncology, Pharmacology +12

18F-FDG PET/CT in non-small-cell lung cancer patients

Laura Evangelista, Lea Cuppari, Jessica Menis et al. · Nuclear Medicine Communications · 2019 · 78 citations

Medicine, Nuclear Medicine, Oncology +17

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

Luca Cantini, Giulia Mentrasti, Gian Luigi Russo et al. · ESMO Open · 2022 · 65 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments

Alessandra Ferro, Matteo Sepulcri, Marco Schiavon et al. · Cancers · 2022 · 21 citations · Full text

Medicine, Oncology, Surgery +17

Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients

M. Lorenzi, Maria Vittoria Resi, Laura Bonanno et al. · Frontiers in Immunology · 2024 · 16 citations · Full text

Medicine, Immunology, Oncology +17